AEZS vs. HBP, BCT, MBX, TH, APS, RVX, ATE, SVA, ONC, and MDNA
Should you be buying Aeterna Zentaris stock or one of its competitors? The main competitors of Aeterna Zentaris include Helix BioPharma (HBP), BriaCell Therapeutics (BCT), Microbix Biosystems (MBX), Theratechnologies (TH), Aptose Biosciences (APS), Resverlogix (RVX), Antibe Therapeutics (ATE), Sernova (SVA), Oncolytics Biotech (ONC), and Medicenna Therapeutics (MDNA). These companies are all part of the "biotechnology" industry.
Aeterna Zentaris (TSE:AEZS) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings, community ranking and institutional ownership.
0.7% of Aeterna Zentaris shares are owned by institutional investors. 4.0% of Aeterna Zentaris shares are owned by insiders. Comparatively, 20.5% of Helix BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Helix BioPharma's return on equity of 0.00% beat Aeterna Zentaris' return on equity.
Helix BioPharma has lower revenue, but higher earnings than Aeterna Zentaris. Helix BioPharma is trading at a lower price-to-earnings ratio than Aeterna Zentaris, indicating that it is currently the more affordable of the two stocks.
Aeterna Zentaris has a beta of 2.08, indicating that its share price is 108% more volatile than the S&P 500. Comparatively, Helix BioPharma has a beta of -0.78, indicating that its share price is 178% less volatile than the S&P 500.
In the previous week, Aeterna Zentaris and Aeterna Zentaris both had 1 articles in the media. Aeterna Zentaris' average media sentiment score of 0.00 equaled Helix BioPharma'saverage media sentiment score.
Helix BioPharma received 58 more outperform votes than Aeterna Zentaris when rated by MarketBeat users. However, 88.89% of users gave Aeterna Zentaris an outperform vote while only 63.46% of users gave Helix BioPharma an outperform vote.
Summary
Aeterna Zentaris beats Helix BioPharma on 6 of the 11 factors compared between the two stocks.
Get Aeterna Zentaris News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aeterna Zentaris Competitors List
Related Companies and Tools
